FDA Toxicity Biomarker Working Groups Voice Data Sharing Concerns

Confidentiality concerns may pose an obstacle to successful information gathering by the cardiotoxicity and vasculitis biomarker expert working groups, working group members suggested at a May 3-4 orientation.